Based on more than 25 years of experience, EPO is providing customized oncology and immuno-oncology services for the preclinical development of novel anti-cancer drugs. Our portfolio includes more than 600 well characterized patient derived xenograft (PDX) models as well as a broad variety of cell-line derived xenografts (CDX) for studies in immuno-deficient, syngeneic or humanized mouse strains. EPO is offering services such as in vivo imaging for our orthotopic and metastasis models, flow cytometry and experimental pathology services including autopsy, histopathology and immunohistochemistry. Our team of highly trained scientists is offering advice for optimized study designs to ensure the best possible outcome for our clients.